Seminars in Oncology
Volume 31, Issue 1 , Pages 47-55 , February 2004

Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers

  • Ram Srinivasan

      Affiliations

    • National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • ,
  • John Barrett

      Affiliations

    • National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • ,
  • Richard Childs

      Affiliations

    • National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • Corresponding Author InformationAddress reprint requests to Richard Childs, MD, NHLBI/NCI, 9000 Rockville Pike, 10/7C103, NIH, Bethesda, MD 20892, USA

References 

  1. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281–287
  2. Negrier S, Escudier B, Lasset C, et al.  Recombinant human interleukin-2, recombinant human interferon alfa 2a, or both in metastatic renal-cell carcinoma. N Engl J Med. 1998;1272–1278
  3. Rosenburg SA, Yang JC, Topalian SL, et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2. JAMA. 1994;271:907–913
  4. Ada G. The coming of age of tumour immunotherapy. Immunol Cell Biol. 1999;77:180–185
  5. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today. 1997;18:267–268
  6. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 1999;5:341–346
  7. Weiden P, Flournoy N, Thomas E, et al.  Antileukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med. 1979;300:1068–1073
  8. Horowitz M, Gale RP, Sondel P, et al.  Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:552–562
  9. Apperley JF, Jones L, Hale G, et al.  Bone marrow transplantation for patients with chronic myeloid leukemia (T cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse). Bone Marrow Transplant. 1986;1:53–68
  10. Kolb HJ, Mittermueller J, Clemm C, et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  11. Kolb H-J, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2047
  12. Heslop HE, Brenner MK, Rooney CM, et al.  Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679–680
  13. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206–4211
  14. Tricot G, Vesole D, Jagannath S, et al.  Graft-versus myeloma effect (Proof of principle). Blood. 1996;87:1196–1198
  15. Verdonck L, Lokhorst H, Dekker A, et al.  Graft-versus-myeloma effect in 2 cases. Lancet. 1996;347:800–801
  16. Jones RJ, Ambinder RF, Piantadosi S, et al.  Evidence of a graft-versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–653
  17. van Besien KW, de Lima M, Giralt SA, et al.  Management of lymphoma recurrence after allogeneic transplantation (The relevance of graft-versus-lymphoma effect). Bone Marrow Transplant. 1997;19:977–982
  18. Papadopoulos EB, Ladanyi M, Emanuel D, et al.  Infusions of donor leukocytes to treat EBV associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–1191
  19. Mehta J, Powles R, Singhal S, et al.  Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease (possible role of graft-versus-leukemia). Bone Marrow Transplant. 1996;17:371–375
  20. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med. 1999;50:507–529
  21. Stevens EJ, Jacklin L, Robbins PF, et al.  Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol. 1995;154:762–771
  22. Moscovitch M, Slavin S. Antitumor effects of allogeneic bone marrow transplantation in (NZB X NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997–1003
  23. Morecki S, Moshel Y, Gelfand Y, et al.  Induction of graft vs. tumor effect in a murine model of mammary carcinoma. Int J Cancer. 1997;71:59–63
  24. Morecki S, Yacovlev E, Diab A, et al.  Allogeneic cell therapy for murine mammary carcinoma. Cancer Res. 1998;58:3891–3895
  25. Eibl B, Schwaighofer H, Nachbaur D, et al.  Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501–1508
  26. Ueno NT, Rondon G, Mirza NQ, et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986–993
  27. Bay JO, Choufi B, Pomel C, et al.  Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant. 2000;25:681–682
  28. Giralt S, Estey E, Albitar M, et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (Harnessing graft versus leukemia without myeloablative therapy). Blood. 1997;89:4531–4536
  29. Slavin S, Nagler A, Naparastak E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  30. Khouri IF, Keating M, Korbling M, et al.  Transplant-lite (Induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  31. Childs R, Clave E, Contentin N, et al.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (Full donor T-cell chimerism preceded alloimmune responses). Blood. 1999;94:3234–3241
  32. McSweeney PA, Niederwieser D, Shiruzu JA. Hematopoietic cell transplantation in older patients with hematologic malignancies (Replacing high-dose cytotoxic therapy with graft-versus-tumor effects). Blood. 2001;97:3390–3400
  33. Sykes M, Preffer F, McAfee S, et al.  Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA mismatched bone-marrow transplantation. Lancet. 1999;353:1755–1759
  34. Childs R, Epperson D, Bahceci E, et al.  Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant (In vivo and in vitro evidence for a graft-versus-leukaemia effect). Br J Haematol. 1999;107:396–400
  35. Childs R, Clave E, Tisdale J, et al.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral blood progenitor cell transplant (Evidence for a graft-versus-tumor effect). J Clin Oncol. 1999;17:2044–2051
  36. Figlin RA, Pierce WC, Kaboo R, et al.  Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997;158:740–745
  37. Mackinnon S, Barnett L, Bourhis JH, et al.  Myeloid and lymphoid chimerism after T-cell depleted bone marrow transplantation (Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA). Blood. 1992;80:3235–3241
  38. Childs R, Chernoff A, Contentin N, et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  39. Rini B, Zimmerman TM, Gajewski TF, et al.  Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001;165:1208–1209
  40. Makimoto A, Mineishi S, Tanosaki R, et al.  Nonmyeloablative stem cell transplantation (NST) for refractory solid tumors. Proc Am Soc Clin Oncol. 2001;20:44; (abstr)
  41. Bregni M, Dodero A, Peccatori J, et al.  Graft-vs-tumor effect in advanced solid tumors following reduced intensity stem cell allografting. Proc Am Soc Clin Oncol. 2001;20:45; (abstr)
  42. Rini B, Zimmerman TM, Gajewski TF, et al.  Allogeneic stem cell transplantation for metastatic renal cell cancer after nonmyeloablative chemotherapy (Engraftment rates, toxicity and initial clinical results). Proc Am Soc Clin Oncol. 2001;20:719; (abstr)
  43. De Buerger M, Bakker A, Van Rood JJ, et al.  Tissue distribution of minor histocompatibility antigens. J Immunol. 1992;149:1788–1794
  44. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197–2207
  45. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol. 1996;8:75–81
  46. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft versus host disease and graft versus leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991;8:51–58
  47. Mena O, Igarashi T, Srinivasan R, et al.  Immunologic mechanisms of the graft-vs-tumor effect in RCC following nonmyeloablative allogeneic transplantation. Blood. 2001;98:856a; (abstr)
  48. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 2000;111:6–17
  49. Schmid C, Lange C, Salat C, et al.  Treatment of recurrent acute leukemia after marrow transplantation with donor cells and GM-CSF. Blood. 1999;94:668a; (suppl 1, abstr 2965)
  50. Pedrazzoli P, Da Prada G, Schiavo R, et al.  Allogeneic peripheral blood stem cell transplantation following reduced intensity chemotherapy in solid tumors. Proc Am Soc Clin Oncol. 2001;20:43; (abstr)

PII: S0093-7754(03)00564-5

doi: 10.1053/j.seminoncol.2003.11.002

Seminars in Oncology
Volume 31, Issue 1 , Pages 47-55 , February 2004

Article Tools

* Image Usage & Resolution